监测0至8岁儿童婴儿期乙型肝炎疫苗接种及再接种的效力:保护性抗-HBs水平与细胞免疫应答
研究在2015年1月至2017年6月随机问卷调查招募1695名学龄前儿童,评估婴儿期乙型肝炎疫苗接种及再接种的效力。1591名按0-1-6月方案完成基础免疫的婴儿中1249名(79.30%)抗-HBs滴度大于10 IU/L;103例无应答者再接种后96例获血清保护。无应答组与高应答组间多种循环免疫细胞存在显著差异。
要点
- 1591名按0-1-6月方案完成基础免疫的婴儿中1249名(79.30%)抗-HBs滴度大于10 IU/L。
- 103例无应答者再接种后96例获得血清保护。
- 无应答组CD8+ T细胞、CD4+CD45RO+ T细胞、CD8+CD45RA+ T细胞和Tfh细胞较高应答组显著增加。
核心结论
- 大多数学龄前儿童在婴儿期接种乙型肝炎疫苗后获得了显著的血清保护。
- 初次接种失败后再接种者的血清转化率显著高于初次接种后。
- 不同疫苗效力组间循环免疫细胞存在显著变化,可能是影响重组HBV疫苗免疫效果的因素。
研究设计与样本
- 采用随机问卷调查,于2015年1月至2017年6月招募1695名学龄前儿童作为研究对象。
- 采集血样检测HBV血清学标志物及外周免疫细胞。
- 根据疫苗效力将儿童分为无应答组(NR)、低应答组(LR)和高应答组(HR)。
- 在再接种完成1个月后评估再接种对NR组的效果。
主要发现
- 1695名儿童中1591名(93.86%)为按0-1-6月方案接受乙型肝炎疫苗基础免疫的婴儿,其中1249名(79.30%)抗-HBs滴度大于10 IU/L。
- 免疫细胞研究显示,NR组CD8+ T细胞、CD4+CD45RO+ T细胞、CD8+CD45RA+ T细胞和Tfh细胞较HR组显著增加。
- NR组淋巴细胞、CD4+ T细胞和CD4+CD45RA+ T细胞低于HR组。
- 103例无应答病例中96例在再接种后显示血清保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination against hepatitis B virus (HBV) is recommended worldwide. The aim of this study was to assess the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children in the context of protective anti-HBs levels and cellular immune responses. Using a random questionnaire survey, 1695 pre-school children were recruited as research subjects during January 2015 to June 2017. Blood samples were obtained to measure HBV serological markers as well as peripheral immunocytes. The children were divided into non-, low- and hyper- responsive groups (NR, LR, and HR) based on the vaccination efficacy. Additionally, the effect of revaccination on the NR group was evaluated at 1 month after completion of the vaccination course. Among a total of 1695 children, 1591 (93.86%) were infants who were followed while undergoing their primary course of hepatitis B vaccination at the 0-1-6 month schedule, and 1249 (79.30%) of them developed antibodies against HBsAg (anti-HBs) titers greater than 10 IU/L. The results of immunocyte studies indicated that the CD8+ T cells, CD4+CD45RO+ T cells, CD8+CD45RA+ T cells, and T follicular helper (Tfh) cells increased significantly in NR compared with HR. However, lymphocytes, CD4+ T cells, and CD4+CD45RA+ T cells in NR were lower than that in HR. 96 of the non-response cases showed seroprotection after revaccination among 103 cases. Therefore, most of the preschool children who received hepatitis B vaccine in infancy achieved significant seroprotection. Seroconversion rates of individuals revaccinated after initial vaccination failure were significantly higher than those after primary vaccination. Different vaccination efficacy groups showed significant changes in circulating immunocytes, which might be a factor affecting the recombinant HBV vaccine's immune effectiveness.
引用
- Li X, Xu Y, Dong Y, et al. Monitoring the efficacy of infant hepatitis B vaccination and revaccination in 0- to 8-year-old children: Protective anti-HBs levels and cellular immune responses. Vaccine. 2018. PMID: 29588118. doi:10.1016/j.vaccine.2018.03.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。